Citi lowered the firm’s price target on Lexicon Pharmaceuticals to $4 from $5 and keeps a Buy rating on the shares. The analyst cites reduced the firm’s lower peak sales estimate for Inpefa in heart failure for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LXRX:
- Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
- Lexicon enrolls first patient in Phase 2b Progress study of LX9211
- Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
- Lexicon presents post hoc analysis of data from SCORED trial
- INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data